Correlation Between Sorafenib Plasma Concentrations, Toxicity and Disease Control Rate in Patients Treated by Sorafenib for Hepatocellular Carcinoma
Phase of Trial: Phase IV
Latest Information Update: 10 Nov 2016
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Acronyms ACTES
- 03 Nov 2016 Planned End Date changed from 1 Sep 2018 to 1 Oct 2018.
- 03 Nov 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Nov 2017.
- 03 Nov 2016 Status changed from not yet recruiting to recruiting.